<DOC>
	<DOCNO>NCT02287597</DOCNO>
	<brief_summary>This local , non-interventional , cohort study patient metastatic colorectal cancer ( mCRC ) prospectively collect data standard clinical practice second-line treatment chemotherapy plus Avastin ( bevacizumab ) . There additional diagnostic therapeutic procedure require study , apart perform everyday clinical practice second-line treatment mCRC Croatia .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Patients With Metastatic Colorectal Cancer : Continued Avastin Plus Chemotherapy After First Progression Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Written inform consent Age &gt; /=18 year Metastatic colorectal cancer ( mCRC ) previously treat systemic treatment advance disease contain Avastin chemotherapy ; firstline Avastin receive accord Summary Product Characteristics ( SmPC ) First line progressionfree survival ( PFS ) &gt; 6 month Eligible secondline chemotherapy regimen Period first progression start second line treatment Avastin chemotherapy &lt; /=6 week Contraindications , warning precaution use specify Avastin SmPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>